Meriwether Wealth & Planning’s Vertex Pharmaceuticals VRTX Stock Holding History

Meriwether Wealth & Planning’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$57K	Buy	+109	New	+$55.8K	0.03%	250

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $39.3B AUM 31.81% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Meriwether Wealth & Planning's VRTX Position: Q3 2026 in Review

Meriwether Wealth & Planning opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 109 shares worth $57K. The stake represents 0.03% of the portfolio and ranks #250 among its holdings.

643 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Meriwether Wealth & Planning held 109 shares of Vertex Pharmaceuticals worth $57K as of Q3 2026.
Vertex Pharmaceuticals was a new Meriwether Wealth & Planning position in Q3 2026.
Vertex Pharmaceuticals made up 0.03% of Meriwether Wealth & Planning's portfolio in Q3 2026, its #250 holding.
643 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Meriwether Wealth & Planning's 13F filing for Q3 2026, filed 13 Oct 2026.